 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/365789
U.S. Emerging Ovarian Cancer Therapeutics Markets
|
Description: |
High Relapse Rate Drives Demand for Expanded Treatment Options
Though chemotherapy is effective in achieving remission in most ovarian
cancer patients, remission often lasts less than two years. Further chemotherapy
provides only limited success. The high relapse rate in these patients will
continue to drive demand for a wider range of therapeutic options. With a
myriad of new products currently in development, this market is poised to
expand rapidly. Given the prevalence of this disease in the U.S., manufacturers
of effective treatments should see impressive gains over the forecast period.
This Frost & Sullivan study analyzes the markets for emerging ovarian cancer
therapeutics, including treatments for localized, metastatic, and
relapsed/refractory cancers. It presents incidence rates for each segment,
reviews existing products, and assesses the potential of products still in
development. By tracking pricing trends and by offering accurate revenue
forecasts, this study gives its users a comprehensive view of the field.
Lack of Clinical Trial Patients Delays Time to Market
With more than forty products in development, competition for suitable
clinical trial patients is fierce, says the study’s author. Patients do not typically
consider clinical trials until they have exhausted all other options. However,
many end-stage patients do not qualify for experimental treatments because
of their extensive history with other therapies.
Nevertheless, clinical trials remain crucial for the acceptance of new
therapies. Drug companies will remain challenged to overcome this significant
barrier to product commercialization, states the anaylst. This study evaluates
industry challenges and provides strategies to help your company surmount
obstacles that may lay ahead.
Patent Expirations and Immunotherapy Changing Market Dynamics
Over the next five years, patents will expire for a number of leading
chemotherapeutic drugs, opening the door for generic competition, says the
author. Although the introduction of generics will threaten revenues for
well-branded products, it will enable new market participants to profit from
established therapies.
Meanwhile, the increasing use of immunotherapy presents an important
prospect for drug makers. Immunotherapeutics will become part of standard
treatment protocol as complementary therapies that can help delay relapse,
prolong survival, and improve quality of life, says the author. By
highlighting new opportunities, this study will help you target the lucrative
areas for growth.
Additional Information
Market Participants
AltaRex, Inc.
ALZA Corp.
Antisoma plc
AstraZeneca Pharmaceuticals
AVAX Technologies, Inc.
Aventis Pharmaceuticals, Inc.
Bristol-Myers Squibb, Inc.
Celgene Corp.
Cytran, Inc.
Eli Lilly
Genaera Corp.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Guilford Pharmaceuticals, Inc.
InterMune Pharmaceuticals, Inc.
Intracel Corp.
Introgen Therapeutics, Inc.
ISIS Pharmaceuticals, Inc.
Johnson & Johnson
Medarex, Inc.
MGI Pharma, Inc.
Millenium Pharmaceuticals, Inc.
NeoPharm, Inc.
Novartis Oncology
Onyx Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc.
Pharmacia Corp.
Roche US Pharmaceuticals
Schering-Plough Corp.
Seattle Genetics, Inc.
SuperGen, Inc.
Telik, Inc.
Vertex Pharmaceuticals, Inc.
Aerospace
Auto ID
Biotech
Chemicals
Conferencing
Consumer
e-Business
Environment
Food
Healthcare
Internet Security
IT
Latin America
Medical Devices
Motors
Pharmaceuticals
Power
Sensors
Smart Cards
Technical Insights
Telecom Services
Transportation
Water
Wireless
|
|
Contents: |
1. Executive Summary
A. Executive Summary
1. Executive Summary
2. Introduction
A. Overview
1. Scope and Segmentation
2. Epidemiology and Etiology
3. Clinical Staging
4. Symptoms and Diagnosis
5. Treatment and Survival
6. Market and Technology Trends
B. Market Dynamics
1. Challenges
2. Drivers
3. Restraints
C. Strategic Recommendations
1. Strategies Overview
2. Strategic Recommendations for Market Challenge 1
3. Strategic Recommendations for Market Challenge 2
4. Strategic Recommendations for Market Challenge 3
5. Strategic Recommendations for Market Challenge 4
6. Strategic Recommendations for Market Challenge 5
D. Frost and Sullivan Market Engineering Awards
1. Technology Innovation Award
2. Strategic Alliance Innovation Award
3. Technology Leadership Award
4. Merger and Acquisition Strategy Award
5. Business Development Strategy Award
3. Localized Ovarian Cancer Market
A. Overview
1. Introduction
2. Existing Therapies
3. Emerging Therapies
4. Market Engineering Analysis
B. Forecasts and Trends
1. Demand Analysis
2. Revenue Forecasts
3. Pricing Trends
C. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
3. Product Analysis-Existing
4. Products Analysis-Emerging
4. Metastatic Ovarian Cancer Market
A. Overview
1. Introduction
2. Existing Therapies
3. Emerging Therapies
4. Market Engineering Analysis
B. Forecasts and Trends
1. Demand Analysis
2. Revenue Forecasts
3. Pricing Trends
C. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
3. Product Analysis-Existing
4. Product Analysis-Emerging Immunotherapeutics
5. Product Analysis-Emerging Chemotherapeutics
5. Relapsed/Refractory Ovarian Cancer Market
A. Overview
1. Introduction
2. Existing Therapies
3. Emerging Therapies
4. Market Engineering Analysis
B. Forecasts and Trends
1. Demand Analysis
2. Revenue Forecasts
3. Pricing Trends
C. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
3. Product Analysis-Existing
4. Product Analysis-Emerging Immunotherapeutics
5. Products Analysis-Emerging Chemotherapeutics
List Of Figures
Chapter 2
Emerging Ovarian Cancer Therapeutics Market: Estimated Age-Adjusted Incidence and Mortality Rates per 100,000 of the Population (U.S.), 2001
Emerging Ovarian Cancer Therapeutics Market: Estimated Incidence and Mortality Rates per 100,000 of the Population by
Race/Ethnicity (U.S.), 2001
Emerging Ovarian Cancer Therapeutics Market: Disease Classification According to the International Federation of Gynecology and Obstetrics and the American Joint Committee on Cancer (U.S.), 2001
Emerging Ovarian Cancer Therapeutics Market: Impact of Top Industry Challenges (U.S.), 2001-2008
Emerging Ovarian Cancer Therapeutics Market: Market Drivers Ranked in Order of Impact (U.S.), 2001-2008
Emerging Ovarian Cancer Therapeutics Market: Market Restraints Ranked in Order of Impact (U.S.), 2001-2008
Emerging Ovarian Cancer Therapeutics Market: Strategies Addressing Market Challenges (U.S.), 2001
Chapter 3
Emerging Ovarian Cancer Therapeutics Market: Total Female Population and Ovarian Cancer Incidence, Prevalence and Mortality (U.S.), 1998-2008
Localized Ovarian Cancer Therapeutics Market: Incidence And Prevalence (U.S.), 1998-2008
Localized Ovarian Cancer Therapeutics Market: Total Treated Population and Total Localized Treated Patient Population (U.S.), 1998-2008
Localized Ovarian Cancer Therapeutics Market: Revenue Forecasts by Product Class (U.S.), 1998-2008
Localized Ovarian Cancer Therapeutics Market: Immunotherapeutic Revenue Forecasts by Product Class (U.S.), 1998-2008
Localized Ovarian Cancer Therapeutics Market: Percent of Revenues by Product Type (U.S.), 1998-2008
Localized Ovarian Cancer Therapeutics Market: Product Pricing (U.S.), 2001
Localized Ovarian Cancer Therapeutics Market: Annual Cost Of Treatment (U.S.), 2000
Localized Ovarian Cancer Therapeutics Market: Competitive Structure (U.S.), 2001
Localized Ovarian Cancer Therapeutics Market: Market Share Analysis (U.S.), 2000-2001
Localized Ovarian Cancer Therapeutics Market: Product Analysis--Existing (U.S.), 2001
Localized Ovarian Cancer Therapeutics Market: Product Analysis—Emerging (U.S.), 2001
Chapter 4
Metastatic Ovarian Cancer Therapeutics Market: Incidence and Prevalence (U.S.), 1998-2008
Metastatic Ovarian Cancer Therapeutics Market: Total Treated Population and Total Metastatic Treated Patient Population (U.S.), 1998-2008
Metastatic Ovarian Cancer Therapeutics Market: Revenue Forecasts by Product Class (U.S.), 1998-2008
Metastatic Ovarian Cancer Therapeutics Market: Immunotherapeutic Revenue Forecasts by Product Class (U.S.), 1998-2008
Metastatic Ovarian Cancer Therapeutics Market: Percent of Revenues by Product Type (U.S.), 1998-2008
Metastatic Ovarian Cancer Therapeutics Market: Product Pricing (U.S.), 2001
Metastatic Ovarian Cancer Therapeutics Market: Annual Cost of Treatment (U.S.), 2001
Metastatic Ovarian Cancer Therapeutics Market: Competitive Structure (U.S.), 2001
Metastatic Ovarian Cancer Therapeutics Market: Market Share Analysis (U.S.), 2000-2001
Metastatic Ovarian Cancer Therapeutics Market: Product Analysis—Existing (U.S.), 2001
Metastatic Ovarian Cancer Therapeutics Market: Product Analysis—Emerging Immunotherapeutics (U.S.), 2001
Metastatic Ovarian Cancer Therapeutics Market: Product Analysis—Emerging Chemotherapeutics (U.S.), 2001
Chapter 5
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Prevalence (U.S.), 1998-2008
Emerging Ovarian Cancer Therapeutics Market: Total Treated Population and Total Relapsed/Refractory Treated Patient Population (U.S.), 1998-2008
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Revenue Forecasts by Product Class (U.S.), 1998-2008
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Immunotherapeutic Revenue Forecasts by Product Class (U.S.), 1998-2008
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Percent of Revenues by Product Type (U.S.), 1998-2008
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Product Pricing (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Annual Cost of Treatment of Single Agents (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Annual Cost of Treatment of Combination Therapy (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Competitive Structure (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Market Share Analysis (U.S.), 2000-2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Product Analysis-- Approved (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Product Analysis--Off-Label (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Product Analysis-- Emerging Monoclonal Antibodies (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Product Analysis-- Emerging Vaccines and Other Immunotherapeutics (U.S.), 2001
Relapsed/Refractory Ovarian Cancer Therapeutics Market: Product Analysis-- Emerging Chemotherapeutics (U.S.), 2001
|
|
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/365789
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 29/08/2008 07:05:13 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
U.S. Emerging Ovarian Cancer Therapeutics Markets
|
|
Web Address: |
http://www.researchandmarkets.com/reports/365789
|
|
Office Code: |
|
OCHGLLQPSUU
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Site License
|
|
€2,696.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€3,719.00
|
|
Electronic and Hard Copy (PDF)
- Enterprisewide
|
|
€4,060.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic and Hard Copy (PDF)
- Site License
|
|
€3,037.00 + EUR€ 50.00 Shipping/Handling *
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646)607-1907 or (646)964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
|
|
Page 2 of 2
Printed 29/08/2008 07:05:13
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646)607-1907 or (646)964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
|
|
|
|
|
|
